A5042734609- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Acute Lymphoblastic Leukemia research
- Chronic Lymphocytic Leukemia Research
- Multiple Myeloma Research and Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- T-cell and B-cell Immunology
- Immune Cell Function and Interaction
- Lymphoma Diagnosis and Treatment
- Renal Transplantation Outcomes and Treatments
- Eosinophilic Disorders and Syndromes
- CAR-T cell therapy research
- Neutropenia and Cancer Infections
- Immunotherapy and Immune Responses
- Cancer Treatment and Pharmacology
- Protein Degradation and Inhibitors
- Histone Deacetylase Inhibitors Research
- Cancer Genomics and Diagnostics
- Cytomegalovirus and herpesvirus research
- Monoclonal and Polyclonal Antibodies Research
- Immunodeficiency and Autoimmune Disorders
- Polyomavirus and related diseases
- Mesenchymal stem cell research
- MicroRNA in disease regulation
University Hospital Leipzig
2016-2025
Leipzig University
2016-2025
Klinik und Poliklinik für Neurologie
2008-2025
Aichi Medical University
2020-2024
Lithuanian University of Health Sciences
2020-2024
Hospital of Lithuanian University of Health Sciences Kaunas Clinics
2024
Aichi Medical University Hospital
2019-2021
Creative Commons
2021
Cairo University
2019
Statistical Service
2019
Chronic myelogenous leukemia (CML) is caused by the BCR-ABL tyrosine kinase, product of Philadelphia chromosome. Imatinib mesylate, formerly STI571, a selective inhibitor this kinase.
Patients with acute myeloid leukemia (AML) and a FLT3 mutation have poor outcomes. We conducted phase 3 trial to determine whether the addition of midostaurin - an oral multitargeted kinase inhibitor that is active in patients standard chemotherapy would prolong overall survival this population.We screened 3277 patients, 18 59 years age, who had newly diagnosed AML for mutations. were randomly assigned receive (induction therapy daunorubicin cytarabine consolidation high-dose cytarabine)...
Abstract The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for diagnosis management acute myeloid leukemia (AML) in adults are widely recognized among physicians investigators. There have been major advances our understanding AML, including new knowledge about molecular pathogenesis leading to an update disease classification, technological progress genomic diagnostics assessment measurable residual disease, successful development therapeutic agents, such as FLT3,...
Neopterin, a compound derived from GTP, represents precursor molecule of biopterin that is an essential cofactor in neurotransmitter synthesis. We have recently reported vivo as well vitro immune responses are accompanied by increased release neopterin and this phenomenon can be used for the biochemical monitoring diseases hyperimmune stimulation. This article deals with cellular origin control response-associated vitro. Using highly purified or monoclonal reagents we demonstrate macrophages...
Acute graft-versus-host disease (GVHD) remains a major limitation of allogeneic stem-cell transplantation; not all patients have response to standard glucocorticoid treatment. In phase 2 trial, ruxolitinib, selective Janus kinase (JAK1 and JAK2) inhibitor, showed potential efficacy in with glucocorticoid-refractory acute GVHD.
Hematopoietic stem cell transplantation (HSCT) requires significant infrastructure. Little is known about HSCT use and the factors associated with it on a global level.To determine current of to assess differences in its application explore associations macroeconomic transplant rates level.Retrospective survey study patients receiving allogeneic autologous HSCTs for 2006 collected by 1327 centers 71 participating countries Worldwide Network Blood Marrow Transplantation. The regional areas...
Background and Objectives There are no widely accepted criteria for the definition of hematopoietic stem cell transplant-associated microangiopathy (TAM). An International Working Group was formed to develop a consensus formulation diagnosing clinically significant TAM.Design Methods The participants proposed list candidate criteria, selected those considered necessary, ranked optional identify core set criteria. Three obligatory four that highest set. In an appropriateness panel process,...
Abstract BACKGROUND: It was investigated whether the European Group for Blood and Marrow Transplantation risk score, previously established chronic myeloid leukemia, could be used to predict outcome after allogeneic hematopoietic stem cell transplantation (HSCT) hematological disease in general. METHODS: Age of patient, stage, time interval from diagnosis transplant, donor type, donor‐recipient sex combination were establish a score 0 7 points. Its validity tested 56,505 patients, 33,113...